Peer-reviewed article
From Polymorphisms to Phenotypes: SMAD3 rs17293632 and LTBP3 rs11545200 in Pediatric Inflammatory Bowel Disease.
Jan Brylak, Mariusz Szczepanik, Jan K Nowak, Małgorzata Jamka, Aleksandra Glapa-Nowak et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a genetic association study examining two DNA polymorphisms (SMAD3 and LTBP3) in children with inflammatory bowel disease in Poland. The researchers found that certain genetic variants were associated with earlier disease onset, poorer nutrition, and different patterns of medication use. The study suggests these genetic markers might help predict disease severity and guide personalized treatment choices.
Key points
- LTBP3 rs11545200 minor allele associated with younger age at IBD diagnosis
- LTBP3 variant linked to poorer nutritional status during disease flares
- LTBP3 variant associated with more frequent infliximab use, particularly in ulcerative colitis
- SMAD3 rs17293632 major homozygous genotype in Crohn's disease associated with increased systemic corticosteroid use
- Study included 286 children (133 with UC, 153 with CD) from seven Polish pediatric centers
Limitations
This is an observational genetic association study with no intervention or comparison group, so it cannot establish causation or whether genetic variants directly cause different disease outcomes. The study identifies associations between genetic markers and clinical presentation but does not evaluate whether using this information improves child health outcomes.
Abstract
Background/Objectives: Early-onset inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), frequently presents with a more severe clinical course. Genetic susceptibility, particularly involving the TGF-β signaling pathway, plays a key role in IBD pathogenesis. SMAD3 and LTBP3 encode crucial components of this pathway and have been implicated in IBD in previous genome-wide association studies. Methods: This study aimed to assess the clinical significance of the rs17293632 (SMAD3) and rs11545200 (LTBP3) polymorphisms in a pediatric IBD cohort. A total of 286 children (133 with UC and 153 with CD) were recruited from seven pediatric centers in Poland. Clinical data included age at diagnosis, inflammatory markers (CRP, albumin), growth indices (Z-scores for weight, height, and BMI), and treatment regimens. Results: The LTBP3 rs11545200 minor allele was significantly associated with a younger age at diagnosis, poorer nutritional status during disease flares, and a more frequent use of infliximab-particularly in patients with UC. In CD, the SMAD3 rs17293632 major homozygous genotype was associated with increased use of systemic corticosteroids, suggesting a more severe or treatment-resistant disease phenotype. Conclusions: The assessed polymorphisms in LTBP3 and SMAD3, both involved in TGF-β signaling, are associated with clinical characteristics of pediatric IBD. These findings support the potential role of genetic variants as biomarkers for disease severity and treatment tailoring, contributing to the development of personalised therapeutic strategies in children with IBD.